PFS

1:44
Improved survival in MM with thalidomide before and after ASCT
Niels van de Donk
1:32
iNNOVATE results: a prospective new standard of care for Waldenström’s
Meletios Dimopoulos
1:56
Randomized trials of pomalidomide combinations for MM
Meletios Dimopoulos
1:48
The MUK Seven trial: tackling the issue of R/R multiple myeloma
Martin Kaiser
1:54
CASTOR trial update: daratumumab/bortezomib/dexamethasone is an important regimen for R/R MM
Katja Weisel
3:17
Results of the GMMG PERSPECTIVE trial: triple regimen for R/R multiple myeloma
Katja Weisel
1:33
The rise of MRD in multiple myeloma: could this be an answer to a cure?
Irene Ghobrial
1:19
Myeloma XI trial: impact of MRD on treatment response in MM
Graham Jackson
1:34
Multiple myeloma highlights at ASH 2017
Graham Jackson
2:22
Myeloma XI trial: lenalidomide maintenance therapy for multiple myeloma
Graham Jackson
2:06
MURANO study: exciting times in CLL
George Follows
2:51
Novel agent filanesib combination therapy for R/R multiple myeloma
Enrique Ocio
3:12
Results of the MURANO study for CLL
Arnon Kater
2:43
Pembrolizumab consolidation therapy in multiple myeloma
Enrique Ocio
1:10
Impacts of the MURANO study for future CLL treatment
Barbara Eichhorst
2:19
Bendamustine plus rituximab vs. standard therapy for advanced CLL
Barbara Eichhorst
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals